The FDA has granted Perspectum, a UK-based imaging diagnostic company, nearly $250,000 to develop a novel biomarker for primary sclerosing cholangitis (PSC), a rare liver disease.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing
The FDA has granted Perspectum, a UK-based imaging diagnostic company, nearly $250,000 to develop a novel biomarker for primary sclerosing cholangitis (PSC), a rare liver disease.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing
We are preparing, please wait
This content is only available for premium members. Please become a paid member to access.
Download AppCurrently, memberships can only be purchased through the app.